Journal
SEMINARS IN CANCER BIOLOGY
Volume 59, Issue -, Pages 36-49Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2019.02.002
Keywords
PI3K; PIK3CA; P110; Cancer; Mutations; Gain-of-function; Oncogenic transformation; AKT; PI3K inhibitors
Categories
Funding
- Israel Science Foundation [696/17]
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [754282]
- ERC [CoG-770854]
- Rising Tide Foundation
- Hamburger Family
- Knell Family
- MRA [402024]
- European Research Council (ERC) [754282] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Almost thirty years ago, PI3K was discovered as a lipid kinase associated with certain oncoproteins. The first decade of research on PI3K saw the identification, purification and cloning of PI3K alpha. The second decade of research was noted for the identification of some of PI3K's activators and effectors. This was accompanied by the discovery that PI3K acts as a retroviral oncogene. The third decade was known for the establishment of the direct involvement of PI3K in cancer, demonstrated by the identification of cancer-specific mutations. Efforts to target PI3K were on the rise from that moment on, accompanied by the first clinical trials for PI3K inhibitor therapies. In the fourth decade of research, PI3K-based cancer drugs will continue to emerge, as will new knowledge regarding other uncovered functions of this protein and pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available